EAM
GBT

Eagle Asset Management’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Eagle Asset Management’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-32,426
Closed -$2.16M – 608
2020
Q2 		$2.16M Sell
32,426
-414,102
-93% -$28.4M 0.01% 441
2020
Q1 		$22.8M Buy
446,528
+2,803
+0.6% +$188K 0.14% 197
2019
Q4 		$35.3M Sell
443,725
-2,286
-0.5% -$135K 0.17% 198
2019
Q3 		$21.6M Buy
446,011
+9,050
+2% +$472K 0.11% 223
2019
Q2 		$23M Buy
+436,961
New +$25.1M 0.12% 226

Other funds holding GBT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Eagle Asset Management's GBT Position: Q3 2020 in Review

Eagle Asset Management sold out of Global Blood Therapeutics, Inc. (GBT) in Q3 2020, closing a stake of 32,426 shares — an estimated $2.16M sold.

Eagle Asset Management first reported a position in GBT in Q2 2019 and held it in 5 quarters. The position peaked at $35.3M in Q4 2019. 229 funds tracked by Wall St. Rank hold GBT as of Q3 2020.

  • Eagle Asset Management reported no remaining Global Blood Therapeutics, Inc. position as of Q3 2020 after selling out during the quarter.
  • Eagle Asset Management sold 32,426 Global Blood Therapeutics, Inc. shares in Q3 2020, an estimated $2.16M.
  • Eagle Asset Management first reported a position in Global Blood Therapeutics, Inc. in Q2 2019 and held it in 5 quarters.
  • Eagle Asset Management's Global Blood Therapeutics, Inc. position peaked at $35.3M in Q4 2019.
  • 229 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q3 2020.

Based on Eagle Asset Management's 13F filing for Q3 2020, filed 12 Nov 2020.